This is a study to evaluate the safety of subcutaneous nogapendekin-alfa inbakicept (N-803/NAI) in participants with Long COVID.
Acceptance Requirements
Adult patients who meet the definition for Long COVID
At least 90 days have elapsed since your last COVID infection
Symptoms for at least 60 days
Symptoms have an impact on quality of life and/or everyday functioning